Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. (AFMD) has been a Nasdaq-listed, clinical-stage immuno-oncology company focused on innate cell engagers (ICE®) generated on its proprietary ROCK® platform. Company news has highlighted how these ICE® molecules are being developed to recognize and kill a range of hematologic and solid tumors by engaging innate immune cells.
News coverage for AFMD includes detailed clinical updates on key ICE® programs such as AFM24, AFM28 and acimtamig (AFM13). Releases describe AFM24 as a tetravalent, bispecific ICE® targeting CD16A and EGFR, with data in advanced or metastatic non-small cell lung cancer, including combinations with atezolizumab. For AFM28, Affimed has reported early Phase 1 results in relapsed/refractory acute myeloid leukemia, including composite complete remission rates and safety findings. Additional news has covered acimtamig in combination with AlloNK® (AB-101) in classical Hodgkin lymphoma, with abstracts accepted for major oncology meetings.
Another important category of AFMD news relates to corporate and listing developments. In May 2025, Affimed announced that it had filed for insolvency proceedings in Mannheim, Germany, citing overindebtedness and liquidity concerns. Shortly thereafter, the company disclosed that Nasdaq staff would suspend trading of its common shares and proceed with a delisting process, culminating in a Form 25 filing to remove its common stock from Nasdaq listing and registration.
On this news page, readers can review historical press releases on AFMD’s clinical trial data, conference presentations, investor webcasts, and regulatory and listing updates. For those tracking the company’s ICE® pipeline and its insolvency and delisting process, this archive offers a centralized view of how Affimed’s scientific, clinical, and corporate story has evolved over time.
Affimed N.V. (AFMD) has received notice from Nasdaq that its common shares will be delisted from the exchange. Trading of AFMD shares will be suspended on May 20, 2025, following the company's insolvency filing in the Mannheim court, Germany, on May 13, 2025.
The delisting decision is based on three key factors: public interest concerns following the insolvency filing, concerns about existing shareholders' residual equity interest, and doubts about the company's ability to maintain Nasdaq listing requirements. Affimed does not plan to appeal this determination.
Affimed N.V. (AFMD), a clinical-stage immuno-oncology company, has announced filing for insolvency proceedings with the local court of Mannheim, Germany. Despite ongoing fundraising efforts, the company failed to secure sufficient capital to continue operations of Affimed N.V. and its subsidiaries Affimed GmbH and Affimed Inc.
The management has determined that both Affimed N.V. and Affimed GmbH are overindebted (Überschuldung), necessitating insolvency filing under German law. As a result of these proceedings, Affimed's common shares will be suspended from trading and subsequently delisted from The Nasdaq Global Market. The company's current liquidity condition raises substantial doubt about its ability to continue as a going concern.
Affimed presented promising results for its cancer drug AFM24 in treating non-small cell lung cancer (NSCLC) at the 2025 AACR Annual Meeting. The study analyzed 72 NSCLC patients, revealing significantly better outcomes in patients with higher drug exposure.
Key findings show patients with above-median drug exposure achieved:
- 33.3% objective response rate vs 5.6% in low-exposure group
- 7.3 months progression-free survival vs 2.9 months
- 83.3% disease control rate vs 58.3%
Based on these results, Affimed will optimize future trials using a higher 720mg weekly dose, which achieves target exposure levels by week two of treatment. Importantly, higher exposure showed no increased safety concerns. The combination therapy with atezolizumab showed consistent benefits, with 37.04% response rate in high-exposure patients versus 7.14% in low-exposure groups.
Affimed N.V. (Nasdaq: AFMD) has announced the acceptance of three abstracts for presentation at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentations include:
1. An oral presentation on the phase 2 LuminICE-203 study of acimtamig in combination with AlloNK® (AB-101) for relapsed or refractory classical Hodgkin lymphoma, scheduled for May 30.
2. Two poster presentations on AFM24 in combination with atezolizumab for non-small cell lung cancer (NSCLC): one focusing on EGFR-expressing NSCLC without driver mutations, and another on NSCLC with EGFR kinase domain mutations. Both posters will be presented on June 2.
The full abstracts will be published online on May 22, 2025.
Affimed N.V. (AFMD) has received a deficiency notice from Nasdaq dated April 15, 2025, due to its stock price closing below the minimum requirement of $1.00 per share for the last 30 consecutive business days. The company has been granted an initial 180-day period until October 13, 2025, to regain compliance with the minimum bid price requirement.
If compliance is not achieved during this period, Affimed may consider transferring from The Nasdaq Global Select Market to The Nasdaq Capital Market, which could provide an additional 180 days (until April 13, 2025) to meet requirements. This transfer would be subject to meeting other listing criteria. The notice does not immediately affect the listing or trading of Affimed's shares.
Affimed N.V. (Nasdaq: AFMD) has announced that their abstract focusing on AFM24 dose optimization has been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25-30, 2025).
The presentation will detail dose optimization using exposure response analysis for AFM24, both as monotherapy and in combination with atezolizumab, in patients with advanced/metastatic non-small cell lung cancer. The poster presentation is scheduled for Tuesday, April 29, 2025, from 9:00 AM to 12:00 PM CDT in Poster Section 49.
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference 2025. The company's CEO, Dr. Shawn Leland, will engage in a fireside chat on Tuesday, March 11, 2025, at 2:20 p.m. EDT.
Investors and interested parties can access a live webcast of the presentation through Affimed's website investor section. The presentation recording will remain available for 30 days following the event. For those interested in one-on-one meetings with Affimed's management team, arrangements can be made through Leerink Partners representatives or by contacting Alex Fudukidis.
Affimed (AFMD) reported positive clinical data from the AFM24-102 trial combining AFM24 with atezolizumab in non-small cell lung cancer (NSCLC) patients. In 33 EGFR wild-type patients, the combination showed a 21% overall response rate and 76% disease control rate, with tumor shrinkage in 48% of patients. The median progression-free survival was 5.6 months.
In 17 EGFR mutant patients, results showed a 24% overall response rate and 71% disease control rate, with tumor shrinkage in 41% of patients. Both patient groups demonstrated manageable side effects. A post-hoc analysis revealed that patients with higher AFM24 exposure had significantly better outcomes, leading to plans for using a higher 720mg weekly dose in future development.
Affimed announced promising Phase 1 data for AFM28 in treating relapsed/refractory Acute Myeloid Leukemia (R/R AML). The study, involving 29 heavily pretreated patients, demonstrated a 40% composite complete remission rate at the highest dose level (300 mg). Key findings include:
- Well-managed safety profile with mainly Grade 1 and 2 infusion-related reactions in 45% of patients
- No neurotoxicity or immune-related side effects
- One complete remission at 250 mg dose level with 6.5-month treatment duration
- At 300 mg dose level, achieved 1 CR and 3 CRi in 10 evaluable patients
The study included patients with a median of two prior treatment lines, with 86% having adverse risk profiles. Based on these results, evaluation of higher dose levels is planned.
Affimed N.V. (Nasdaq: AFMD) announced it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, a combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The call will be accessible via phone and webcast through the company's website, with dial-in details provided upon registration. A replay will be available for 30 days following the call.
FAQ
What is the current stock price of Affimed (AFMD)?
What is the market cap of Affimed (AFMD)?
